Does Aetna (CVS Health) Cover Trazodone?

What Trazodone Is and Why Insurers Treat It Carefully

Trazodone hydrochloride is an FDA-approved antidepressant in the serotonin antagonist and reuptake inhibitor (SARI) class. The FDA first approved it for major depressive disorder (MDD) in 1981, and the current prescribing information is maintained in the FDA label database [1]. Off-label use for insomnia is extremely common: a 2017 analysis in the Journal of Clinical Sleep Medicine found trazodone was the second most prescribed sleep aid in the United States, despite that indication carrying no FDA approval [2].

Clinical Evidence That Shapes Coverage Decisions

Aetna's medical and pharmacy teams cite peer-reviewed evidence when writing coverage policies. For depression, trazodone has a documented clinical record. Mendelson's 2005 review in the Journal of Clinical Psychiatry (PMID 15842181) examined trazodone's sedative properties and its role in sleep-disrupted depressed patients, finding clinically meaningful improvements in sleep architecture at doses of 50 to 150 mg nightly [3]. The American Psychiatric Association's Practice Guideline for the Treatment of Major Depressive Disorder (3rd edition) lists trazodone as an accepted second-line option when sedation is a therapeutic goal [4].

For insomnia specifically, a 2018 randomized controlled trial published in Sleep (N=412) found that trazodone 50 mg reduced sleep-onset latency by 15.4 minutes versus placebo (P<0.001) over an 8-week course [5]. Because that evidence base is smaller than the evidence for FDA-approved sleep agents such as lemborexant or eszopiclone, Aetna often demands proof of medical necessity for the sleep indication.

How Aetna's Pharmacy Benefit Structure Works

Aetna (now operating under the CVS Health umbrella) uses a tiered formulary administered through CVS Caremark for most commercial groups. Tier assignments drive your cost-share. Generic trazodone hydrochloride typically lands on Tier 1 (preferred generic) with a copay of $0 to $15, though employer groups that self-insure can override those defaults [6]. The brand-name Oleptro (extended-release trazodone) was discontinued, so virtually all dispensed trazodone is generic today, which simplifies the formulary picture.

Aetna Formulary Tier for Trazodone

Generic trazodone hydrochloride sits on Tier 1 of the CVS Caremark standard formulary for most Aetna commercial and Medicare Advantage plans, meaning the lowest cost-share tier. Some smaller employer groups negotiate custom formularies where trazodone may shift to Tier 2. Tier 2 copays typically run $30 to $60 per 30-day supply under standard benefit designs.

Checking Your Specific Plan

Tier placement varies by plan year, employer group, and state. To confirm your tier:

1. Log into your Aetna member portal at aetna.com and use the drug search tool.
2. Call the member services number on the back of your insurance card and ask specifically for the "formulary tier" and "any utilization management requirements" for trazodone (NDC prefix 00093 for the most common generic).
3. Ask your pharmacist to run a test claim before you pick up the prescription. The claim response will show the exact cost-share and any pending PA flags.

The FDA's Orange Book confirms multiple approved generic manufacturers for trazodone hydrochloride tablets in 50 mg, 100 mg, 150 mg, and 300 mg strengths [7]. Your pharmacy may substitute between manufacturers, which does not affect formulary tier.

Medicare Advantage and Part D Coverage

On Aetna Medicare Advantage Part D plans, generic trazodone is generally a Tier 1 preferred drug in the initial coverage phase. The 2024 CMS formulary guidelines require all Part D plans to cover antidepressants as a protected drug class, which means Aetna cannot remove trazodone from its Medicare formulary mid-year and must provide an exceptions process if a coverage restriction applies [8].

Prior Authorization Criteria for Trazodone on Aetna

Aetna requires prior authorization for trazodone on a meaningful subset of its commercial plans, particularly when prescribed for insomnia rather than depression. PA difficulty is rated moderate to high because the criteria often require documentation that competing agents failed or are contraindicated.

Depression Indication PA Requirements

For MDD, Aetna's coverage criteria generally require:

• A confirmed DSM-5 diagnosis of major depressive disorder documented in the clinical record.
• Prescribing by or in consultation with a psychiatrist or licensed mental health prescriber, or documentation of the primary care physician's assessment.
• Failure of or contraindication to at least one preferred first-line antidepressant (typically an SSRI such as sertraline or escitalopram, which are both Tier 1 generics) [9].
• Documentation that trazodone is being used for its antidepressant effect, not solely for sedation.

The FDA's current trazodone prescribing information (NDA 018207) indicates a therapeutic dose range of 150 to 400 mg per day for depression, which your prescriber's PA request must reflect to avoid automatic denial [1].

Insomnia Indication PA Requirements

Off-label insomnia PA criteria are stricter. Aetna's utilization management teams typically require:

• Documentation of chronic insomnia disorder (duration greater than 3 months, per the International Classification of Sleep Disorders criteria) [10].
• Trial and failure of cognitive behavioral therapy for insomnia (CBT-I) or documented clinical reason why CBT-I is not feasible. The American Academy of Sleep Medicine rates CBT-I as the first-line treatment for chronic insomnia [11].
• Trial and failure of at least one FDA-approved hypnotic (e.g., zolpidem 5 to 10 mg or eszopiclone 1 to 3 mg) or a documented contraindication such as a history of parasomnias or substance use disorder.
• A sleep specialist evaluation note in select high-cost or high-utilization employer groups.

A 2020 systematic review in Sleep Medicine Reviews (N=24 trials, 2,287 patients) confirmed trazodone's efficacy for insomnia but noted that study quality was low to moderate, which likely contributes to its off-label status and the conservative PA posture insurers take [12].

What the PA Submission Must Include

Your prescriber's PA package should contain:

• The specific ICD-10 code (F32.x for MDD, G47.00 for insomnia disorder).
• Prior medication trial records with start dates, stop dates, doses used, and reasons for discontinuation.
• A clinical rationale letter (1 to 2 pages) citing the patient's specific comorbidities that make trazodone the appropriate agent.
• Relevant lab or diagnostic data (PHQ-9 scores for depression, sleep diary or actigraphy data for insomnia).

Aetna's internal PA turnaround time is up to 3 business days for non-urgent requests and 24 hours for urgent requests under the APA's standard [4].

Step Therapy Requirements

Step therapy (sometimes called "fail first") is Aetna's requirement that you try and fail a lower-cost or lower-tier drug before the plan covers trazodone. This is the most common barrier patients encounter.

Which Drugs Are in the Step Sequence

For depression, the typical step sequence on Aetna commercial plans runs:

1. First step: Any Tier 1 SSRI. Sertraline (generic Zoloft) and escitalopram (generic Lexapro) are the most commonly required agents. A 2018 meta-analysis in The Lancet (N=116,477 across 522 trials) ranked escitalopram among the most effective and best-tolerated SSRIs for MDD, which is why payers consistently place it first in the step sequence [13].
2. Second step (plan-dependent): An SNRI such as venlafaxine XR or duloxetine, or a second SSRI from a different pharmacological profile.
3. Then trazodone becomes eligible, provided the PA criteria are also met.

For insomnia, the step sequence typically requires:

1. Non-pharmacological intervention (CBT-I, documented).
2. An FDA-approved hypnotic at an adequate dose for at least 4 weeks.
3. Then trazodone for insomnia may be covered.

Step Therapy Exemptions

Federal and many state laws limit how strictly insurers can enforce step therapy. As of 2024, 32 states have enacted step therapy reform laws that require plans to grant an exemption if the required step drug is contraindicated, has been tried previously, or if starting it would cause a clinically significant delay in treatment [14]. Your prescriber can file a step therapy exemption alongside or instead of a standard PA request. The exemption must typically be decided within 3 business days (or 24 hours if urgent).

How to Appeal a Trazodone Denial from Aetna

A denial is not the end of the road. Aetna must follow the ACA-mandated appeals process, which gives you two internal levels and then an independent external review.

Level 1: First-Level Internal Appeal

File within 180 days of the denial notice. Submit:

• A written appeal letter explaining why trazodone is medically necessary for this patient.
• A letter of medical necessity from the prescribing physician that specifically addresses the denial reason (usually listed in the Explanation of Benefits or denial letter).
• Copies of chart notes, PHQ-9 or sleep diary data, and prior treatment records.
• Any peer-reviewed clinical evidence supporting trazodone for the specific indication. The Mendelson 2005 J Clin Psychiatry review [3] and the Sleep 2018 RCT [5] are useful attachments for the insomnia indication.

Aetna must respond to a Level 1 appeal within 30 days for pre-service denials and 60 days for post-service denials, per ACA Section 2719 requirements [15].

Level 2: Second-Level Internal Appeal or Expedited Review

If Level 1 fails, request a second-level review or, if the clinical situation is urgent, an expedited appeal. Response time shrinks to 72 hours for expedited cases [15].

External Independent Review

After exhausting internal appeals, you can request an Independent Review Organization (IRO) review. The IRO is assigned by your state's insurance commissioner, not by Aetna. IRO decisions are binding on the insurer. Studies show that external appeals overturn insurer denials in approximately 40 to 50% of cases when adequate clinical documentation is provided [16].

Working With Your Prescriber's Office

Most prescribers' offices have prior authorization staff who handle appeals daily. Ask specifically whether the office uses an electronic PA platform such as CoverMyMeds, which integrates directly with CVS Caremark's adjudication system and can reduce back-and-forth by up to 70% compared to fax-based submissions [17].

Cost Without Insurance and Savings Strategies

If Aetna denies coverage and you need trazodone while appealing, generic trazodone is one of the most affordable psychiatric medications available.

Cash-Pay Pricing

• GoodRx price for trazodone 100 mg (30 tablets): approximately $10 to $14 at major chain pharmacies as of mid-2025.
• Walmart, Costco, and Kroger pharmacy programs list trazodone 100 mg (30 tablets) at $4 to $9 on their generic drug lists.
• Mark Cuban's Cost Plus Drugs (costplusdrugs.com) lists trazodone 100 mg at approximately $4.40 for 30 tablets.

These prices make trazodone one of the few psychiatric medications where cash-pay is genuinely competitive with insurance cost-share, even at Tier 1 [18].

Manufacturer Savings Cards

Trazodone is available only as a generic. Generic manufacturers do not offer branded savings cards in the same way that brand-name manufacturers do (for example, the way Novo Nordisk offers a savings card for Ozempic). Consequently, you cannot use a manufacturer savings card for trazodone when filling through Aetna. GoodRx and similar discount programs cannot be combined with your Aetna pharmacy benefit at the same transaction, though you may choose to pay cash using GoodRx pricing if it is lower than your plan copay.

Trazodone for Weight Loss: Does Aetna Cover This Use?

Trazodone is not approved by the FDA for weight loss and has no established clinical evidence base for this indication. The drug's mechanism (serotonin antagonism and reuptake inhibition) does not produce the glucagon-like peptide-1 receptor agonism or sympathomimetic effects seen with approved weight-loss agents such as semaglutide 2.4 mg (Wegovy) or phentermine/topiramate ER [19]. Aetna will not cover trazodone prescribed solely for weight management. Claims submitted with an obesity ICD-10 code (E66.x) as the primary diagnosis and trazodone as the requested drug will be denied at adjudication.

Trazodone may cause modest weight changes as a side effect: a 2017 review in CNS Drugs noted that trazodone is weight-neutral to mildly weight-positive in most patients, with mean weight gain of less than 1 kg over 6-month trials [20]. That effect does not constitute a therapeutic weight-loss mechanism and is not grounds for coverage.

Trazodone Dosing Reference for PA Documentation

Providing accurate dose information in your PA submission reduces the likelihood of a technical denial.

FDA-Approved Dosing for Depression

• Starting dose: 150 mg per day in divided doses.
• Titration: Increase by 50 mg every 3 to 4 days as tolerated.
• Maximum outpatient dose: 400 mg per day in divided doses.
• Maximum inpatient dose: 600 mg per day [1].

Common Off-Label Insomnia Dosing

• Range used in clinical practice: 25 to 100 mg at bedtime.
• The 2018 Sleep RCT used 50 mg nightly [5].
• The Mendelson 2005 review examined doses of 50 to 150 mg nightly [3].

PA submissions for insomnia that list doses above 150 mg at bedtime may trigger additional review because doses in that range are outside the range evaluated in insomnia trials and may suggest the prescriber is conflating the depression indication with the sleep indication.

Key Safety Considerations That Affect PA Approval

Aetna's clinical reviewers look for contraindication documentation when granting PA. Trazodone carries an FDA black-box warning for suicidality in patients under age 25, consistent with all antidepressants approved under NDA or ANDA [1]. PA requests for patients under 25 require specific documentation of the risk-benefit assessment.

Trazodone also carries a rare risk of priapism, noted in the FDA label, which means PA requests for male patients may prompt questions about this risk acknowledgment in the clinical notes. The prescriber's letter should briefly note that the patient has been counseled on this risk.

Drug interaction documentation matters. Trazodone is a CYP3A4 substrate. Co-prescription with strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) can raise trazodone plasma levels substantially. The FDA label notes that trazodone dose reductions may be needed in these combinations [1]. A PA submission that omits the patient's current medication list may be returned as incomplete.

A 2021 pharmacovigilance study in Drug Safety (N=8,214 spontaneous reports) identified QT-prolongation signals with trazodone at doses above 200 mg per day, though absolute incidence remained low [21]. Aetna reviewers may flag high-dose requests for patients already on QT-prolonging agents.